Category: Oncotarget

Oncotarget News

Figure 1: Demographic factors, comorbidities and therapy regime of the melanoma patients in percentage, age in years.

Oncotarget | Impact of Covid-19 on Management of Patients With Metastatic Melanoma

January 11, 2023

In this study, we aimed to analyze our experience with patients suffering from Sars-CoV-2 infection while receiving treatment for metastatic melanoma.” BUFFALO, NY- January 11, 2023 – A new research... read more

Figure 4: Wnt pathway expression in tumors from NeuT/ATTAC mice.

Oncotarget

Oncotarget | Resistance of MMTV-NeuT/ATTAC Mice to Anti-PD-1 Immune Checkpoint Therapy is Associated With Macrophage Infiltration and Wnt Pathway Expression

January 5, 2023

One of the impediments to successful cancer therapy is the heterogeneity and cellular plasticity of the tumor and TME [22, 23].” BUFFALO, NY- January 5, 2023 – A new research... read more

Oncotarget

Oncotarget | Serum microRNAs as New Criteria for Referral to Early Palliative Care Services in Treatment-Naïve Advanced Cancer Patients

December 29, 2022

The most important finding was the development of an objective prediction model for patients admitted to a PCU within 6 months among treatment-naïve advanced cancer patients.” —BUFFALO, NY-... read more

Oncotarget

Oncotarget | Role of Pyrethroid Derivatives in Autophagy and Apoptosis Crosstalk Signaling and Potential Risk for Malignancies

December 28, 2022

Pyrethroid derivatives and related products exposure have revealed to intensify various ailments and adverse health consequence in the different age groups [...]” —BUFFALO, NY- December 28, 2022 – A new research... read more

Oncotarget

Oncotarget | Plasma Growth Hormone a Potential Biomarker of Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma Patients

December 22, 2022

In conclusion, our study demonstrate[s] that plasma GH represents a candidate biomarker for predicting treatment outcomes in patients with advanced HCC treated with Atezo/Bev.”—BUFFALO, NY- December 22,... read more

“Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention.”

Oncotarget

Behind the Study: APOE Genotype Determines Cancer Patients Most Likely to Benefit From Exercise

December 13, 2022

Dr. Kerri Winters-Stone and Dr. Jacob Raber from Oregon Health and Science University, describe a research paper they co-authored that was published by Oncotarget in Volume 13, entitled, “Association of... read more

Oncotarget

Oncotarget | Combined Epigenetic and Immunotherapy for Blastic and Classical Mantle Cell Lymphoma

December 13, 2022

Here, we describe results using cladribine based combination epigenetic and immunotherapy in MCL [mantle cell lymphoma].”BUFFALO, NY- December 13, 2022 – A new research paper was published in Oncotarget's Volume... read more

Oncotarget

Oncotarget | Expression of p-STAT3 and c-Myc Correlates With P2-HNF4α Expression in Nonalcoholic Fatty Liver Disease (NAFLD)

December 6, 2022

In conclusion, our results suggest that STAT3 phosphorylation occurs in livers with NAFLD only in the subset with P2-HNF4α expression, and c-Myc expression is strongly correlated with STAT3 phosphorylation.”BUFFALO,... read more

Oncotarget

Oncotarget | Essential Amino Acids as Diagnostic Biomarkers of Hepatocellular Carcinoma Based on Metabolic Analysis

December 1, 2022

The current and previous findings provide a rationale for further investigations into the potential utility of leucine, valine, and tryptophan as diagnostic and prognostic biomarkers for HCC.”BUFFALO, NY- December... read more

Oncotarget

Oncotarget | Myeloid-Derived Suppressor Cells: Cancer, Autoimmune Diseases, and More

November 29, 2022

MDSCs are heterogeneous immature myeloid cells that possess important actions in immune tolerance and tumor expansion.”BUFFALO, NY- November 29, 2022 – A new review was published in Oncotarget's Volume 13... read more